Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study

Core Insights - Incyte (INCY) reported 54-week data from its late-stage STOP-HS program, showing substantial and sustained efficacy of povorcitinib in patients with moderate-to-severe hidradenitis suppurativa (HS) [1][10] Clinical Trial Overview - The STOP-HS clinical trial program consists of two phase III studies, STOP-HS1 and STOP-HS2, evaluating the efficacy and safety of povorcitinib in adult patients with moderate to severe HS [2] - Both studies include a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week double-blind extension period [2] Efficacy Results - Across both STOP-HS1 and STOP-HS2 trials, treatment responses remained durable through week 54, with up to 71.4% of patients achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) [3] - Higher response thresholds were also notable, with up to 57% reaching HiSCR75 and up to 29% achieving complete response (HiSCR100) [3] Safety and Patient Outcomes - Povorcitinib delivered consistent reductions across key inflammatory lesion types, with complete lesion clearance observed in up to 20% of patients [4] - The safety profile remained consistent with prior data, with both dose levels well tolerated over 54 weeks, supporting a favorable long-term benefit-risk profile [4] Regulatory Status - The new drug application and marketing authorization application for povorcitinib are under review by the FDA and the European Medicines Agency, respectively [7] - The latest data from the STOP-HS program reinforce povorcitinib's potential as a differentiated oral JAK1 inhibitor [7] Pipeline and Future Expectations - Incyte expects top-line phase III data for povorcitinib in vitiligo and prurigo nodularis in mid-2026 and fourth-quarter 2026, respectively [8] - Incyte's efforts to develop new drugs to diversify its portfolio and add incremental revenue streams are notable [11] Financial Performance - Incyte's lead drug Jakafi accounts for the majority of revenues, with shares surging 50.6% in the past year compared to the industry's 14.7% growth [11] - Sales in all indications continue to be strong, with encouraging uptake of new drugs like Pemazyre, Monjuvi, and Tabrecta contributing to top-line growth [13]